Cochrane · systematic review · CD009324

Losigamone add‐on therapy for focal epilepsy

Chen, H, He, H, Xiao, Y, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library

Epilepsy4 versionsAMSTAR 2: not assessed

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.

Questions

current version

GRADE rated

No studies

Included studies

No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 100%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Current version only

Losigamone compared to placebo for focal epilepsy

Population: people with focal epilepsy

CD009324.PUB5 (current) · 4 questions

Outcome	Effect	Evidence	Status / GRADE
50% or greater reduction in seizure frequency Losigamone vs placebo	RR 1.76 [1.14, 2.72]	2 studies · 467 participants	Moderate Downgraded: risk of bias
Treatment withdrawal Losigamone vs placebo	RR 2.16 [1.28, 3.67]	2 studies · 467 participants	Moderate Downgraded: risk of bias
The proportion of participants experiencing any adverse events Losigamone vs placebo	RR 1.34 [1, 1.8]	2 studies · 467 participants	Moderate Downgraded: risk of bias
Adverse event (dizziness) Losigamone vs placebo	RR 3.82 [1.69, 8.64]	2 studies · 467 participants	Moderate Downgraded: risk of bias

Losigamone compared to placebo for focal epilepsy

Population: people with focal epilepsy

CD009324.PUB4 · 4 questions

Outcome	Effect	Evidence	Status / GRADE
50% or greater reduction in seizure frequency Losigamone vs placebo	RR 1.76 [1.14, 2.72]	2 studies · 467 participants	Moderate Downgraded: risk of bias
Treatment withdrawal Losigamone vs placebo	RR 2.16 [1.28, 3.67]	2 studies · 467 participants	Moderate Downgraded: risk of bias
The proportion of participants experiencing any adverse events Losigamone vs placebo	RR 1.34 [1, 1.8]	2 studies · 467 participants	Moderate Downgraded: risk of bias
Adverse event (dizziness) Losigamone vs placebo	RR 3.82 [1.69, 8.64]	2 studies · 467 participants	Moderate Downgraded: risk of bias

Losigamone compared to placebo for partial epilepsy

Population: partial epilepsy

CD009324.PUB3 · 4 questions

Outcome	Effect	Evidence	Status / GRADE
50% or greater reduction in seizure frequency Losigamone vs placebo	RR 1.76 [1.14, 2.72]	2 studies · 467 participants	Moderate Downgraded: risk of bias
Treatment withdrawal Losigamone vs placebo	RR 2.16 [1.28, 3.67]	2 studies · 467 participants	Moderate Downgraded: risk of bias
The proportion of participants experiencing any adverse events Losigamone vs placebo	RR 1.34 [1, 1.8]	2 studies · 467 participants	Moderate Downgraded: risk of bias
Adverse event (dizziness) Losigamone vs placebo	RR 3.82 [1.69, 8.64]	2 studies · 467 participants	Moderate Downgraded: risk of bias

Losigamone compared to placebo for partial epilepsy

Population: partial epilepsy

CD009324.PUB2 · 4 questions

Outcome	Effect	Evidence	Status / GRADE
50% or greater reduction in seizure frequency Losigamone vs placebo	RR 1.76 [1.14, 2.72]	2 studies · 467 participants	Moderate Downgraded: risk of bias
Treatment withdrawal Losigamone vs placebo	RR 2.16 [1.28, 3.67]	2 studies · 467 participants	Moderate Downgraded: risk of bias
The proportion of participants experiencing any adverse events Losigamone vs placebo	RR 1.34 [1, 1.8]	2 studies · 467 participants	Moderate Downgraded: risk of bias
Adverse event (dizziness) Losigamone vs placebo	RR 3.82 [1.69, 8.64]	2 studies · 467 participants	Moderate Downgraded: risk of bias